Astec LifeSciences has announced significant leadership changes alongside improved Q3FY26 financial performance, with the company reporting a 61% reduction in consolidated net loss and 31% revenue growth. The agrochemicals company also disclosed key management transitions including CFO resignation and appointment.

Q3FY26 Financial Performance

The company delivered strong operational improvements across key financial metrics for the quarter ended December 31, 2025:

Leadership Changes and Management Transition

The Board of Directors noted the resignation of Ms. Mugdha Amol Khare as Chief Financial Officer, effective from the close of business hours on March 6, 2026. She is resigning to pursue career opportunities outside the company.

Mr. Deepak Jawaharlal Ochani, a qualified Chartered Accountant and member of ICAI, will take over as CFO from April 1, 2026. He brings extensive expertise in financial management, compliance, governance, and has strong capabilities in financial planning and analysis, budgeting, and working capital management.

Revenue Growth and Segment Performance

Astec LifeSciences achieved consolidated total income of ₹125.5 crore in Q3FY26, representing a 31% increase from ₹95.8 crore in the corresponding quarter of the previous year. The growth was driven by improved performance across both business segments:

EBITDA Turnaround and Exceptional Items

The company achieved positive EBITDA of ₹4.8 crore in Q3FY26, compared to an EBITDA loss of ₹3.8 crore in Q3FY25. According to Chairman N B Godrej, the company delivered strong revenue growth recording 1.3x growth over Q3FY25 driven by higher Enterprise volumes and improved offtake in the Contract Manufacturing segment.

Exceptional items of ₹2.1 crore in Q3FY26 primarily arose from regulatory changes related to four Labour Codes notification by the Government of India, affecting gratuity and long-term compensated absences due to revised wage definitions.

Nine Months Performance Overview

For the nine months period ended December 31, 2025, the company showed consistent improvement:

Astec lifesciences has announced the resignation of Mugdha Amol Khare from her position as Chief Financial Officer of the company. This leadership change represents a significant development in the company's executive structure.

Leadership Transition

The departure of Mugdha Amol Khare from her role as CFO marks an important transition in the financial leadership of ASTEC Lifesciences. As Chief Financial Officer, Khare held a key position in overseeing the company's financial operations, strategic planning, and fiscal management.

Corporate Impact

The resignation creates a vacancy in one of the most critical executive positions at ASTEC Lifesciences. The CFO role is essential for maintaining financial oversight, regulatory compliance, and strategic financial planning within the organization. The company will need to initiate the process of identifying and appointing a suitable successor to ensure continuity in financial management operations.